By signal seeking Phase II studies, we mean studies to evaluate the safety signals, when bavituximab is given along with different chemotherapeutic agents in advanced breast and lung cancer patients. In addition, our second goal was to look for early signs of antitumor activity from these combinations, which would support advancing the program to definitive Phase II trials.
By definitive, we’re referring to studies to sign to solidly confirm patient benefits for patients receiving the combination of bavi plus chemotherapy, versus the standard treatment of chemotherapy alone, this is the ultimate goal of virtually every development program in oncology and are the types of studies that can support eventual product licensure.
Dec 10 2009 conference call. ANY QUESTIONS?
Market Data 
Markets 
AI
